Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
Verona Pharma to Present at Jefferies London Healthcare Conference
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...
KXAN1mon
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...
pharmaphorum4mon
Verona’s first-in-class COPD drug ‘could transform market’
The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...
Mena FN1mon
Verona Pharma To Present Six Analyses Of The Phase 3 ENHANCE Studies In COPD At CHEST 2024
The analyses are published in the CHEST Annual Meeting on-line supplement. Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and ...
PBS1d
The Latest
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.